Furthermore, GATA2 deficiency syndrome patients have a high predisposition to develop (pediatric) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with a median age of onset of 17 years (Wlodarski et al., 2016; Homan et al., 2021), however, before the onset of malignancy, the disease is also life-threatening due to anemia, bleeding disorders, or immunodeficiency with nontuberculous mycobacterial infections (NTM), fungal infections, and human papillomavirus (HPV) infections (Spinner et al., 2014; Ganapathi et al., 2015; Calvo and Hickstein, 2023). Here, GATA2 is linked to myelodysplastic syndrome.